Parkinson's disease (PD) is a devastating neurodegenerative disease characterized by
progressive destruction of dopaminergic tissue in the central nervous system (CNS). To …

As the world's population ages, the incidence of Parkinson's disease (PD), the second most
common neurological ailment, keeps increasing. It is estimated that 1% of the global …

Current therapies for Parkinson's disease are symptomatic and unable to regenerate the
brain tissue. In recent years, the therapeutic potential of a wide variety of neuroprotective …

Parkinson's disease (PD) affects around ten million people worldwide and is considered the
second most prevalent neurodegenerative disease after Alzheimer's disease. In addition …

Parkinson's disease (PD) is characterized by a progressive loss of dopaminergic neurons
and represents a growing health burden to western societies. Like many neurodegenerative …

Nanoparticles might be produced and manipulated to present a large spectrum of
properties. The physicochemical features of the engineered nanomaterials confer to them …

Abstract Parkinson's disease (PD), although being the second most prevalent
neurodegenerative disease (ND) encounters lack of definitive treatment and challenges in …

Current treatments for Parkinson's disease (PD) are aimed at addressing motor symptoms
but there is no therapy focused on modifying the course of the disease. Successful treatment …

Introduction The current treatment modalities available for Parkinson's disease (PD) prove
inadequate due to the inherent constraints in effectively transporting bioactive compounds …

The current pharmacological treatments for Parkinson's disease only offer symptomatic relief
to the patients and are based on the administration of levodopa and catechol-O …